Entos Pharmaceuticals’ Post

Great to see the growth across the industry in not just the big players, but also providers excelling in specialised areas. With a new wave of collaborations and mergers rising, how we can collectively leverage this momentum to expedite next-generation therapies?  #CDMOGrowth #PharmaceuticalInnovation #StrategicPartnerships

.....The moves mark a big bet on a new strategy, and it comes with trade-offs. By shifting its focus from third-line to frontline large B cell lymphoma, Allogene Therapeutics is tapping a larger market opportunity while sidestepping direct competition with existing CAR-T therapies, but that also means it will take longer to generate pivotal data and potentially seek regulatory approval...... #pivot #newstrategy #frontlinetherapies #carttherapies #offtheshelf #allogeneic #therapeutics #celltherapy #cellandgenetherapy #advancedtherapies #regenerativemedicine #biotech #biotechnology #lifesciences #biotech #biotechnology #restructuring #liquidbiopsy #MRD David Chang #patientaccess #marketaccess

Developing oligonucleotide therapeutics? On the 21st May, I will be presenting a live webinar showcasing Patsnap's groundbreaking chemical modification search tool. Identifying modifications in sequences has previously been a laborious and incredibly time consuming task, but thanks to our comprehensive modification ontologies, and AI extraction model, these pains are a thing of the past. Come along to find out how we can revolutionise your oligonucleotide development. #RNA #oligonucleotide #innovation #chemicalmodification

Voyager Therapeutics, Inc. (NASDAQ:VYGR) shares rallied more than 30% in Tuesday pre-market trading after the company announced a strategic collaboration and capsid license agreement worth up to $1.2 billion with Novartis Pharma to advance potential #genetherapies for Huntington’s #disease (HD) and spinal #muscularatrophy (SMA). The #biotechnology company said it will provide Novartis Pharma, a subsidiary of Novartis AG (ADR) (NYSE:NVS), a target-exclusive license to access its TRACER capsids and other intellectual property for the respective #diseases. The two companies will then collaborate to advance a preclinical gene therapy candidate for HD. More at #Proactive #ProactiveInvestors http://ow.ly/SXBH1057A8c #NASDAQ #VYGR

🎉 ProofPilot's webinar is happening NOW!! 🎉 Join our esteemed panelists who chat innovation in small pharma and biotech –sharing how they know firsthand that innovation isn't just for big companies. We're live NOW, 12 pm EST! Register and join here 👉https://hubs.la/Q02xKT8j0 Join us with Rezolute, Inc., Terns Pharmaceuticals, Geneos Therapeutics, and Yonalink!! #clinicalresearch #healthtechnews #clinicaltrialsday

How do you ensure life-saving cell or gene therapy doses are delivered safely when each dose must be stored at cryogenic temperatures 24/7, even during shipping and handling? Biocair demonstrated how by developing a comprehensive and personalized cold chain logistics plan for a biopharmaceutical company’s autologous cell therapy. The Biocair CGT team deployed our evo DV10 Smart Shippers to protect and monitor these high-value samples throughout delivery. View the Case Study below to learn more about Biocair’s solution. Ask us questions about the evo DV10: https://lnkd.in/eK6eQpMp #coldchain #logistics #shipping #biopharma #sampletransport *Case study published in collaboration with Phacilitate.

Don't get stuck trying to use a nuclease that 'gets close' to where you want to edit in the genome because there is not a PAM sequence close by - close is not good enough. Use a nuclease that provides you the flexibility you need to edit your desired gene target. One of the many benefits of Synthego Corporation's hfCas12Max is its broad PAM sequence recognition profile, which enables gene editing in locations previously deemed uneditable using current nuclease options. Casey Jowdy does a great, easy-to-follow walkthrough about hfCas12Max and its abilities in a variety of gene editing applications. #CRISPR

Orchard Therapeutics’ (NASDAQ: ORTX) Shares Skyrocket: How To Predict Biotech M&A Orchard Therapeutics (NASDAQ: ORTX) experienced a remarkable 97% surge in its shares following a major announcement on October 5th, 2023. The renowned global gene therapy leader, Orchard, has been successfully acquired by Kyowa Kirin (OTC: KYKOF), solidifying its position as a fully owned subsidiary. The Agreement: The agreement outlines that Kyowa plans to buy all […] The post Orchard Therapeutics’ (NASDAQ: ORTX) Shares Skyrocket: How To Predict Biotech M&A first appeared on Micro Cap Daily. The post Orchard Therapeutics’ (NASDAQ: ORTX) Shares Skyrocket: How To Predict Biotech M&A appeared first on Micro Cap Daily.

📢 Exciting News! Registration is now open for the 2024 ISPE Biotechnology Conference. 🎉 We’re taking you to Boston, MA, and also offering a virtual experience. 🌐 Get ready to dive into educational sessions that focus on the unique challenges and opportunities in the world of innovative pharmaceutical products. 🧪💊 We’ll be exploring everything from cell and gene therapy to Advanced Therapeutic Medicinal Products (ATMPs), and mRNA-based product development. 🧬🔬 Here’s a sneak peek of what we’ll cover: 🤖 AI & Automation: Redefining how we work in ATMPs and gene therapy. 📊 Data Science in Tech Transfer: Utilizing data science in biopharmaceutical tech transfer and process characterization. 🌿 Sustainability: Innovative strategies to increase sustainability in the biopharmaceutical industry. 📝 Quality & Regulatory: The value of digitalized Quality Management in ensuring effective and compliant quality systems. 💡 Novel Technology Innovations: Technological advancements in pharmaceutical manufacturing. ⏱️ Lifecycle Strategies: Strategies for accelerating commercialization and time-to-market. 🏭 Facility Design: Challenges, trends, and driving factors behind Biopharmaceutical Facility Design. Don’t miss this chance to stay at the forefront of biotechnology advancements. Register now & join us in shaping the future of biotech together! 💡🌐 #ISPE2024 #Biotechnology #Innovation #Pharmaceuticals #Conference